Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting Phase 3 Interventional Study
Pulmonary Disease, Chronic Obstructive (COPD)
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 85
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
594 (estimated)
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Able to understand and follow the protocol requirements, and give written informed consent prior to participation voluntarily in the study. 2. Male or female adults ages 40 to 85 years old when signing the informed consent. 3. Current or former smokers with a smoking history …
Contacts

Qinghong Zhou, Master

+86 18911301578

zhouqinghong@3sbio.com

CONTACT